Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

November 18, 2015

Primary Completion Date

February 26, 2021

Study Completion Date

September 7, 2023

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Gemtuzumab ozogamicin (GO)

Trial Locations (21)

13005

Hôpital de la Conception, Marseille

42270

Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez

45100

CHU d'Orléans, Orléans

78157

CH Versailles, Le Chesnay

92140

HIA Percy, Clamart

Unknown

C.H.U d'Amiens - Hôpital Sud, Amiens

Hôpital V. Dupouy, Argenteuil

CH Avicenne, Bobigny

CHU Caen, Caen

Hopital Henri Mondor, Créteil

CHU Dijon, Dijon

CH Dunkerque, Dunkirk

Hôpital Huriez, CHU de Lille, Lille

CHU Limoges, Limoges

Hopital Necker, Paris

Hopital St Louis, Paris

Hôpital Saint Antoine, Paris

CHU Lyon Sud, Pierre-Bénite

Centre H Becquerel, Rouen

IGR, Villejuif

06100

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Versailles Hospital

OTHER

NCT02473146 - Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 | Biotech Hunter | Biotech Hunter